Cefazolin
- Generic Name
- Cefazolin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14N8O4S3
- CAS Number
- 25953-19-9
- Unique Ingredient Identifier
- IHS69L0Y4T
- Background
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
- Indication
Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.
- Associated Conditions
- Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
- Associated Therapies
- Antibiotic pre-surgical prophylaxis
Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane
- Conditions
- Preterm Premature Rupture of Membrane
- Interventions
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 151
- Registration Number
- NCT01503606
- Locations
- 🇰🇷
Samsung Medical center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Cefazolin Pharmacokinetics: Elimination Clearance in Neonates
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 40
- Registration Number
- NCT01295606
Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair
- Conditions
- Inguinal Hernia
- Interventions
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2014-12-29
- Lead Sponsor
- Diskapi Teaching and Research Hospital
- Target Recruit Count
- 276
- Registration Number
- NCT01273818
- Locations
- 🇹🇷
Diskapi Yildirim Beyazit Teaching and research Hospital, Ankara, Turkey
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
- Conditions
- Infection, Soft TissueInfection, WoundCellulitisDiabetic Foot Ulcer
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Sonescence, Inc.
- Registration Number
- NCT01238276
- Locations
- 🇺🇸
Sonoma West Medical Center, Sebastopol, California, United States
Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX
- Conditions
- Infection
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- B. Braun Medical Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01121354
- Locations
- 🇺🇸
PAREXEL Early Phase Clinical Unit, Baltimore, Maryland, United States
Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)
- Conditions
- Arrythmias
- Interventions
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 500
- Registration Number
- NCT01002911
- Locations
- 🇨🇦
Institut universitaire de cardiologie et de pneumologie de Quebec, Ste-Foy, Quebec, Canada
Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Istanbul University
- Target Recruit Count
- 150
- Registration Number
- NCT00867295
- Locations
- 🇹🇷
Istanbul University Institute of Oncology, Istanbul, Capa, Turkey
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Phillip Brian Smith
- Target Recruit Count
- 9
- Registration Number
- NCT00850122
- Locations
- 🇧🇷
Federal University of Sao Paulo, Sao Paulo, Brazil
Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy
- Conditions
- Antibiotic Prophylaxis
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 251
- Registration Number
- NCT00818766
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery
- Conditions
- Cesarean SectionInfection
- Interventions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- MemorialCare
- Target Recruit Count
- 50
- Registration Number
- NCT00811603
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇺🇸Long Beach Memorial Medical Center, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.